BD (Becton, Dickinson and Company, BDX) reported net income from continuing operations of $692 million in the fiscal fourth quarter of 2026, ended September 30, compared with $345 million in the same period a year earlier. Earnings per share (EPS) from continuing operations was $2.52, versus $1.20 a year earlier. Adjusted EPS (non-GAAP, which excludes items the company considers outside normal operations) was $4.15, up 27.3%.
Revenue for the quarter totaled $5.3 billion ($5,274 million), up 5.4%, or 5.6% in constant currency. In the United States, revenue was $3,204 million (+4.3%), and internationally, $2,070 million (+7.0%). By segment, Interventional had $1,472 million (+7.6%), Medical Essentials $1,786 million (+5.9%), BioPharma Systems $748 million (+6.5%) and Connected Care $1,269 million (+1.6%).
In fiscal year 2026, revenue was $19.5 billion ($19,457 million), up 4.9%. Net income from continuing operations was $1.4 billion ($1,417 million), with EPS of $5.06, and adjusted EPS was $12.70. Total net income was $1.1 billion ($1,145 million), down 31.7%, with a loss of $271 million from discontinued operations. Cash generated by continuing operations rose 30.0% to $3.6 billion, and free cash flow rose 42.5% to $2.9 billion. The company repurchased $2.4 billion in shares and paid $1.2 billion in dividends during the year.
For fiscal year 2027, BD projects low-single-digit revenue growth and adjusted EPS of $13.10 to $13.30. The company also said it will hold its Investor Day on December 10 at the New York Stock Exchange.
